BofA upgraded Erasca (ERAS) to Buy from Neutral with an unchanged price target of $5. The firm cites what it views as a favorable risk-reward for the company’s pan-RAS and pan-KRAS assets heading into “a wealth of clinical updates” over the course of 2025.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener